The latest phase I research on the use of the programmed death-ligands 1 and 2 (PD-L1 and PD-L2)/VISTA pathway co-antagonists (drug: CA-170) show a relevant anti-neoplastic effect in patients with advanced solid tumours or lymphomas who have progressed or are non-responsive to available therapies and for whom no standard therapy exists (NCT02812875) [421] (Figure 2E). Here, PDCD1LG2 is linked to lymphoma.